These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16215315)

  • 1. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
    Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
    Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
    Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
    Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
    Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
    Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
    Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Bmi-1 is a prognostic marker in bladder cancer.
    Qin ZK; Yang JA; Ye YL; Zhang X; Xu LH; Zhou FJ; Han H; Liu ZW; Song LB; Zeng MS
    BMC Cancer; 2009 Feb; 9():61. PubMed ID: 19228380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
    Fang J; Zhang M; Li Q
    Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
    Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p63 gene expression study and early bladder carcinogenesis.
    Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
    Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
    Cho KS; Oh HY; Lee EJ; Hong SJ
    Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
    Friedman JM; Liang G; Liu CC; Wolff EM; Tsai YC; Ye W; Zhou X; Jones PA
    Cancer Res; 2009 Mar; 69(6):2623-9. PubMed ID: 19258506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.